Abstract:Systemic iron homeostasis is strictly controlled under normal conditions to ensure a balance between the absorption, utilization, storage and recycling of iron. The hepcidin-ferroportin (FPN) axis is of critical importance in the maintenance of iron homeostasis. Hepcidin deficiency gives rise to enhanced dietary iron absorption, as well as to increased iron release from macrophages, and this in turn results in iron accumulation in the plasma and organs, and is associated with a range of tissue pathologies. Low hepcidin levels have been demonstrated in most forms of hereditary hemochromatosis (HH), as well as in β-thalassemia. Therapies that increase hepcidin concentrations may potentially play a role in the treatment of these iron overload-related diseases. To date, natural compounds have not been extensively investigated for this purpose, to the best of our knowledge. Thus, in the present study, we screened natural compounds that have the potential to regulate hepcidin expression. By performing hepcidin promoter-luciferase assay, RT-qPCR and animal experiments, we demonstrated that icariin and berberine were potent stimulators of hepcidin transcription. Mechanistic experiments indicated that icariin and berberine increased hepcidin expression by activating the signal transducer and activator of transcription 3 (Stat3) and Smad1/5/8 signaling pathways. The induction of hepcidin was confirmed in mice following icariin administration, coupled with associated changes in serum and tissue iron concentrations. In support of these findings, the icariin analogues, epimedin A, B and C, also increased hepatic hepcidin expression. However, these changes were not observed in hepcidin-deficient [Hamp1-/- or Hamp1‑knockout (KO)] mice following icariin administration, thereby verifying hepatic hepcidin as the target of icariin. Although berberine exhibited a robust capacity to promote hepcidin expression in vitro, it failed to alter hepcidin expression in mice. Taken together, the findings of the present study suggest that icariin exhibits a robust capacity to increase hepatic hepcidin expression and to modulate systemic iron homeostasis. The present study therefore highlights the significance of using natural compounds to ameliorate iron disorders through the regulation of hepcidin expression.

Icariin and its metabolites regulate lipid metabolism: From effects to molecular mechanisms

Determination of Rat Urinary Metabolites of Icariin in Vivo and Estrogenic Activities of Its Metabolites on MCF-7 Cells.

Preparation of Two Derivatives from Icariin and Investigation of Their Estrogen-Like Effects

Icariin Attenuates Vascular Endothelial Dysfunction by Inhibiting Inflammation Through GPER/Sirt1/HMGB1 Signaling Pathway in Type 1 Diabetic Rats

Icariin and its metabolites as potential protective phytochemicals against cardiovascular disease: From effects to molecular mechanisms

Icariin attenuates the enhanced prothrombotic state in atherosclerotic rabbits independently of its lipid-lowering effects.

Metabolic Profiling of Icariin in Rat Feces, Urine, Bile and Plasma after Oral Administration Using Ultra-High Performance Liquid Chromatography/quadrupole Time-of-flight Mass Spectrometry

Impact of Icariin and its derivatives on inflammatory diseases and relevant signaling pathways

AMPK/PGC-1α/GLUT4-Mediated Effect of Icariin on Hyperlipidemia-Induced Non-Alcoholic Fatty Liver Disease and Lipid Metabolism Disorder in Mice

Anti-inflammatory and immunoregulatory effects of icariin and icaritin

Icariin and Its Pharmaceutical Efficacy: Research Progress of Molecular Mechanism

Pharmacokinetics, Tissue Distribution, and Metabolism Study of Icariin in Rat

Icariin Regulates Systemic Iron Metabolism by Increasing Hepatic Hepcidin Expression Through Stat3 and Smad1/5/8 Signaling

Icariin alleviates ferroptosis‐related atherosclerosis by promoting autophagy in xo‐LDL‐induced vascular endothelial cell injury and atherosclerotic mice

Progress of pharmacological research on icariin]

Anti-Alzheimers molecular mechanism of icariin: Insights from gut microbiota and metabolome combined network pharmacology

Icariin Alleviates Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome by Improving Liver Fatty Acid Oxidation and Inhibiting Lipid Accumulation

Effects of icariin on inflammation model stimulated by lipopolysaccharide in vitro and in vivo]

Icariin Derivative Inhibits Inflammation Through Suppression Of P38 Mitogen-Activated Protein Kinase And Nuclear Factor-Kappa B Pathways

Investigating the anti-inflammatory effects of icariin: A combined meta-analysis and machine learning study

Icaritin Attenuates Lipid Accumulation by Increasing Energy Expenditure and Autophagy Regulated by Phosphorylating AMPK